• 1  Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15–9. Cross Ref link Pubmed link
  • 2  Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta‐analysis of prospective studies. JAMA 1998;279(15):1200–5. Cross Ref link Pubmed link
  • 3  Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63(2):136–47. Cross Ref link Pubmed link
  • 4  Leendertse AJ, Egberts AG, Stoker LJ, van den Bemt PA, Group HS. Frequency of and risk factors for preventable medication‐related hospital admissions in the netherlands. Arch Intern Med 2008;168(17):1890–6. Pubmed link
  • 5  Co‐ordination Group for Mutual Recognition and Decentralised Procedures – Human. CMDh Questions and Answers: Biologicals. 2012. http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_269_2012_Rev0_2012_10.pdf (last accessed January 2015).
  • 6  Buxton ILO, Beret LZ. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism and elimination. In: Brunton LL, Chabner BA, Knollman BC, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th edn. New York: McGraw Hill Medical, 2011:17–40.
  • 7  Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004;93(9):2184–204. Cross Ref link Pubmed link
  • 8  Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 2012;3(4):73–92. Cross Ref link Pubmed link
  • 9  Dostalek M, Gardner I, Gurbaxani B, Rose R, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically‐based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013;52(2):83–124. Cross Ref link Pubmed link
  • 10  Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84(5):548–58. Cross Ref link Pubmed link
  • 11  Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotech 2008;26:1261–9. Cross Ref link
  • 12  Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010;15(1–2):40–56. Cross Ref link Pubmed link
  • 13  Li X, Yu M, Fan W, Gan Y, Hovgaard L, Yang M. Orally active‐targeted drug delivery systems for proteins and peptides. Expert Opin Drug Deliv 11(9):1435–47. Cross Ref link Pubmed link
  • 14  Mager DE. Target‐mediated drug disposition and dynamics. Biochem Pharmacol 2006;72(1):1–10. Cross Ref link Pubmed link
  • 15  Tabrizi MA, Tseng C‐ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11(1–2):81–8. Cross Ref link Pubmed link
  • 16  Blumenthal DK, Garrison JC. Pharmacodynamics: molecular mechanisms of drug action. In: Brunton LL, Chabner BA, Knollman BC, eds. Goodman and ­Gilman's The Pharmacological Basis of Therapeutics, 12th edn. New York: McGraw Hill Medicine, 2011:41–72.
  • 17  Kearns GL, Abdel‐Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Eng J Med 2003;349(12):1157–67. Cross Ref link
  • 18  Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41(2):67–76. Cross Ref link Pubmed link
  • 19  McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56(2):163–84. Cross Ref link Pubmed link
  • 20  Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289(9):1107–16. Cross Ref link Pubmed link
  • 21  Zhang M, Holman CDAJ, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 2009;338:a2752. Cross Ref link Pubmed link
  • 22  Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol 1993;7(2):175–7. Cross Ref link Pubmed link
  • 23  Chi C, Wang S, Mayon‐White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population‐based cohort study. JAMA Dermatol 2013;149(11):1274–80. Cross Ref link Pubmed link
  • 24  Ke AB, Rostami‐Hodjegan A, Zhao P, Unadkat JD. Pharmacometrics in pregnancy: an unmet need. Ann Rev Pharmacol Toxicol 2014;54(1):53–69. Cross Ref link
  • 25  Hyrich KL, Verstappen SMM. Biologic therapies and pregnancy: the story so far. Rheumatology 2014;53(8):1377–85. Cross Ref link Pubmed link
  • 26  Nørgård B, Pedersen L, Jacobsen J, Rasmussen SN, Sørensen HT. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004;19(6):679–85. Cross Ref link Pubmed link
  • 27  Weber‐Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low‐dose methotrexate: an observational cohort study. Rheumatology 2014;53(4):757–63. Cross Ref link Pubmed link
  • 28  Huang S‐M, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: us food and drug administration update on cyp enzymes, transporters, and the guidance process. J Clin Pharmacol 2008;48(6):662–70. Cross Ref link Pubmed link
  • 29  Gorski JC, Huang S‐M, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome p450 activity in vivo. Clin Pharmacol Ther 2004;75(1):89–100. Cross Ref link Pubmed link
  • 30  Tateishi T, Miura M, Suzuki T, Uno T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008;65(5):693–700. Cross Ref link Pubmed link
  • 31  Huang SM, Zhao H, Lee JI, et al. Therapeutic protein–drug interactions and implications for drug development. Clin Pharmacol Ther 2010;87(4):497–503. Cross Ref link Pubmed link
  • 32  National Institute for Health and Care Excellence. Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence. 2009. http://guidance.nice.org.uk/CG76/NiceGuidance/pdf/English (last accessed January 2015).
  • 33  Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao, X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;Issue 2:CD000011. Pubmed link
  • 34  Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. ­Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007;41(9):15. Cross Ref link
  • 35  Dean B, Schachter M, Vincent C, Barber N. Causes of prescribing errors in hospital inpatients: a prospective study. Lancet 2002;359(9315):1373–8. Cross Ref link Pubmed link
  • 36  Van Doormaal JE, van den Bemt PMLA, Mol PGM, et al. Medication errors: the impact of prescribing and transcribing errors on preventable harm in hospitalised patients. Qual Safety Health Care 2009;18(1):22–7. Cross Ref link
  • 37  Rinke ML, Bundy DG, Velasquez CA, et al. Interventions to reduce pediatric medication errors: a systematic review. Pediatrics 2014;134(2):338–60. Cross Ref link Pubmed link
  • 38  Nuckols TK, Smith‐Spangler C, Morton SC, et al. The effectiveness of computerized order entry at reducing preventable adverse drug events and medication errors in hospital settings: a systematic review and meta‐analysis. Syst Rev 2014;3(56):12. Cross Ref link Pubmed link
  • 39  Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet 2014;15(1):349–70. Cross Ref link Pubmed link
  • 40  Cavallari LH, Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther 2014;96(1):22–4. Cross Ref link Pubmed link
  • 41  Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S‐methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58(4):8.
  • 42  Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S‐methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126(8):608–14. Cross Ref link Pubmed link
  • 43  Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007;32(2):187–95. Cross Ref link Pubmed link
  • 44  Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008;128(8):1925–9. Cross Ref link Pubmed link
  • 45  Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genom 2013;23(10):563–85. Cross Ref link
  • 46  Mallal S, Phillips E, Carosi G, et al. HLA‐B*5701 screening for hypersensitivity to abacavir. N Eng J Med 2008;358(6):568–79. Cross Ref link
  • 47  Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10(7):507–19. Cross Ref link Pubmed link
  • 48  Directive 2010/63/EU of the European Parliament and of the Council. On the Protection of Animals used for Scientific Purposes, 22 September 2010. http://eur‐lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF (last accessed January 2015).
  • 49  Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti‐CD28 monoclonal antibody TGN1412. N Eng J Med 2006;355(10):
1018–28. Cross Ref link
  • 50  Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010;153(3):158–66. Cross Ref link Pubmed link
  • 51  Goldacre B, Heneghan C. Improving, and auditing, access to clinical trial results. BMJ 2014;348:g213. Cross Ref link Pubmed link
  • 52  Saito H, Gill CJ. How frequently do the results from completed US clinical trials enter the public domain? – A statistical analysis of the ClinicalTrials.gov database. PLOS One 2014;9(7):e101826. Cross Ref link Pubmed link
  • 53  Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 2012;344:d7292. Cross Ref link Pubmed link